Clinical trials: Pancreatic Cancer Non-resectable, open to volunteers
Non-Resectable Pancreas Carcinoma
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer.
- Trial name
- NCT07235930
- Testing
- Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab, AG chemotherapy
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Zhejiang Cancer Hospital
Pancreatic Fluid Collections, Biliary Obstruction
EUS Procedures Using RIVOS™ EUS Access Device
This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.
- Conditions
- Pancreatic Fluid Collections, Biliary Obstruction, Pancreatic Duct Obstruction, Chronic Pancreatitis
- Trial name
- NCT07696572
- Testing
- EUS-guided intervention using the RIVOS™ EUS access device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Orlando Health, Inc.
Pancreatic Cancer Metastatic
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study is an Ib/II phase clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a second-line treatment for unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07342725
- Testing
- IBI363 + chemotherapy
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of…
- Conditions
- Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
- Trial name
- CanPan-C (NCT06605430)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- HealthPartners Institute
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Understanding New Cachexia Subtypes Through Observational Epidemiological Research
The UNCOVER study is a longitudinal observational cohort focused on patients at high risk for cancer cachexia. At Kaiser Permanente Northern California, up to 800 individuals with advanced or unresectable non-small cell lung…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- UNCOVER (NCT07776353)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic health record review
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Kaiser Permanente
Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
This study is a single-arm phase I/II clinical study to evaluate the effectiveness of evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard…
- Trial name
- NCT06888648
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, mFOLFIRINOX Treatment Regimen, Sintilimab injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or…
- Trial name
- NCT06885034
- Testing
- Risvutatug Rezetecan
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 346 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline
EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer
This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
- Conditions
- Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
- Trial name
- NCT07698613
- Testing
- ASP-1929 photoimmunotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer Non-resectable
A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma.
- Trial name
- NCT07898683
- Testing
- Transarterial Radioembolization
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Pancreatic Cancer, Pancreatic Acinar Carcinoma
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread.
- Trial name
- NCT07756281
- Testing
- SNV1521, daraxonrasib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- ParVation Therapeutics, Inc.
Pancreas Cancer, Non-Resectable Pancreas Carcinoma
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination…
- Trial name
- NCT05841420
- Testing
- Gemcitabine, Nab paclitaxel
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Morten Ladekarl
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Clinical trial phase: Phase 2 Intervention model: Control group Group allocation: Randomized controlled trial Research perspective: Prospective study Participating centers: Multicenter study Definition of the intervention period…
- Conditions
- Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
- Trial name
- Dulastin (NCT06135896)
- Testing
- Tripegfilgrastim
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Ductal Adenocarcinoma
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or…
- Trial name
- STOP-PC (NCT06079346)
- Testing
- OT-101, mFOLFIRINOX
- Where
- 2 sites in United States
- Volunteers
- 455 people
- Sponsor
- Oncotelic Inc.
Pancreatic Cancer
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of…
- Trial name
- NCT07033689
- Testing
- Suizenji (an ultrasound-guided HIFU therapy system), Nal-IRI/FL, mFOLFIRINOX adjuvant chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- SONIRE Therapeutics Inc.
IRE
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have…
- Trial name
- NCT07799935
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer, Pancreatic Cancer Metastatic
Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical Cases
Combining retrospective observational research with artificial intelligence data engineering. Collecting historical electronic medical record data, and through data governance and annotation by artificial medical experts…
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07713823
- Volunteers
- 3,000 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation…
- Conditions
- Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
- Trial name
- NCT04789486
- Testing
- AGuIX, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute